New directions for biologic targets in urothelial carcinoma

Molecular Cancer Therapeutics
Suzanne Richter, Srikala S Sridhar

Abstract

Urothelial carcinoma remains an important oncologic problem with significant morbidity and mortality. This article provides an overview of the current status of treatment of urothelial carcinoma, with an update on current trials and recent American Society of Clinical Oncology abstracts. As an alternative to focusing on the metastatic setting, we take a broad look at drug development to date, as it spans from early disease to advanced disease in the context of emerging molecular data. This approach allows us to show that each stage involves key considerations based on emerging evidence regarding molecular biology, stage-specific novel endpoints, and rational patient selection that may help further trial designs in the future. Key issues, such as neoadjuvant versus adjuvant perioperative chemotherapy, approaches to salvage second-line therapy in the metastatic setting, and treatment of elderly and cisplatin-ineligible patients, are discussed. New paradigms in clinical research, including novel endpoints, upfront rational patient selection, biomarkers, and trial design, are also addressed.

References

Jul 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerB A Lowe
Nov 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M CoppinL D Sullivan
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N SternbergUNKNOWN European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
Jan 5, 2002·Expert Opinion on Investigational Drugs·M C Filion, N C Phillips
May 29, 2002·Surgical Oncology·Edward H Streeter, Adrian L Harris
Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Jul 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J SweeneyDonald S Kaufman
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha H A HussainUNKNOWN National Cancer Institute
Jul 16, 2008·Nature Clinical Practice. Urology·David J Gallagher, Dean F Bajorin
Dec 2, 2008·Nature Reviews. Drug Discovery·Alexei VazquezGareth L Bond
Jan 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G K PhilipsUNKNOWN Cancer and Leukemia Group B
Jul 8, 2009·Actas urologicas españolas·Marko BabjukUNKNOWN Asociación Europea de Urología
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Nov 20, 2009·PloS One·Laura E MacConaillLevi A Garraway
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Loren K MellRalph R Weichselbaum
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J GallagherDean F Bajorin
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntJonathan E Rosenberg
Jun 18, 2010·Expert Review of Anticancer Therapy·Liang ChengAntonio Lopez-Beltran
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Jul 28, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Christina Barbara Ching, Donna Elizabeth Hansel
Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ananya ChoudhuryRichard A Cowan
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noah M HahnUNKNOWN Hoosier Oncology Group
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN International Collaboration of TrialistsMahesh K B Parmar
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew D GalskyJoaquim Bellmunt
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerRichard J Cote
Nov 22, 2011·The Journal of Urology·Bas W G van RhijnBharati Bapat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.